Can-Fite BioPharma (CANF) announced that a leading group from University of Los Angeles, UCLA, demonstrate that Piclidenoson showed efficacy in an experimental model of vascular dementia. The study headed by Dr. S. Thomas Carmichael, M.D., Ph.D., Professor and Chair Frances Stark Chair, Department of Neurology, Geffen School of Medicine at UCLA, utilized a vascular dementia mouse model with focal ischemia replicating many elements of the complex pathophysiology of human vascular dementia. Piclidenoson was found to restore tissue integrity and behavioral function in this vascular dementia model.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma files to sell 4.9M American depositary shares
- Can-Fite BioPharma’s Shareholders Approve Key Proposals at Annual Meeting
- Can-Fite BioPharma Reschedules Annual Meeting Due to Lack of Quorum
- Can-Fite BioPharma to Present Pancreatic Cancer Study Progress at BIO 2025
- Can-Fite BioPharma to present Phase IIa pancreatic cancer study progress